---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-122267"
form_type: "8-K"
ticker: "RBOT"
cik: "0001812173"
company_name: "Vicarious Surgical Inc."
filed_at: "2025-12-16T23:59:59+00:00"
generated_at: "2026-05-16T13:05:15.594904+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vicarious Surgical guides FY2026 cash burn ~$35M (improved from $45M); NYSE to delist warrants

## Summary
- FY2026 cash burn guidance of ~$35M, a $10M improvement over the recently updated $45M 2025 guidance.
- Additional cash needs beyond existing resources to achieve design freeze on Vicarious Surgical system are ~$25M.
- Design freeze targeted by year-end 2026; cost reductions from headcount and consulting partially offset by strategic outsourcing.
- NYSE to delist and immediately suspend trading in the Company's warrants (RBOT.WS) due to abnormally low price levels. No appeal.
- Entered into ATM agreement with H.C. Wainwright for potential sale of up to ~$2.3M of common stock (based on Form S-3 limitation); 3% commission.

## SEC filing metadata
- accession: 0001213900-25-122267
- form_type: 8-K
- ticker: RBOT
- cik: 0001812173
- company_name: Vicarious Surgical Inc.
- filed_at: 2025-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/ea0269650-8k_vicarious.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-122267
- JSON: https://secwatch.observer/filing/0001213900-25-122267.json
- Plain text: https://secwatch.observer/filing/0001213900-25-122267.txt

## Source-grounded claims
- claim_id: 5ac5563b2bc5d7d7e2020bf5a8971b122472f637
  claim: Vicarious Surgical Inc. received a nyse noncompliance notice notice regarding market value (rules 802.01B).
  evidence_excerpt: YSE’s determination. Trading in the Company’s Common Stock will be unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock remains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of the NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026, and continued compliance with the NYSE’s other continued listing requirements.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm
- claim_id: 5f563bb55e46331bcd71ba559cb5e97e6385b73a
  claim: Vicarious Surgical Inc. received a nyse delisting notice notice regarding other (rules 802.01D).
  evidence_excerpt: December 15, 2025, the NYSE notified the Company that the NYSE has determined to (a) commence proceedings to delist the Company’s warrants, with thirty warrants exercisable for one share of Common Stock, at an exercise price of $345.00 per share, and listed to trade on the NYSE under the symbol “RBOT.WS” (the “Public Warrants”) and (b) immediately suspend trading in the Public Warrants due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The Company does not intend to appeal the NYSE’s determination. Trading in the Company’s Common Stock w
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.